Consistently, Wan’s research demonstrates that a decrease of EZH2 is beneficial for podocyte injury by antagonizing Wilm’s tumor 1 (WT1) in diabetic nephropathy [14]. This evidence concerns the gene WT1 and diabetic kidney disease.